PD-184352 was the first MEK inhibitor to enter clinical trials and it demonstrated inhibition of activated ERK and anti-tumor activity in patients [25,26]; however, subsequent multicenter, phase II studies with patients with diverse solid tumors did not demonstrate encouraging results [27]. Here, MAP2K7 is linked to neoplasm.